evelopment of a dual CD1a/CCR9-directed CAR-T therapy for the treatment of R/R T-cell acute lymphoblastic leukemia

Principal Investigator

Cristina Prat

File

CPP2022-009759,

Duration

2023 – 2026

Funded by

Agencia Estatal de Investigación

Funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR.

Objective

To develop a new immunotherapy option for patients with relapsed or refractory T-cell acute lymphoblastic leukemia who are not eligible for stem cell transplantation.